Aclarion (ACON) Stock News

Aclarion (Nasdaq: ACON, ACONW) will participate in the 38th Annual ROTH Conference March 22-24, 2026, in Dana Point, CA to meet institutional investors and analysts.

CEO Brent Ness will hold one-on-one meetings to discuss progress advancing Nociscan, the company’s MR spectroscopy platform, and emphasize a strong balance sheet, no debt, and plans to expand adoption in the UK and US.

Aclarion (Nasdaq: ACON) announced that CEO Brent Ness will attend LSI USA 2026 in Dana Point, CA, March 16-20, 2026, to meet investors and potential partners.

Mr. Ness will discuss progress advancing NOCISCAN, Aclarion’s MR spectroscopy platform using biomarkers and AI to help identify painful vs non-painful spinal discs. Investors may request 1-on-1 meetings via the provided contact emails.

Aclarion (Nasdaq: ACON) published its 2026 shareholder letter outlining clinical, financial, and operational priorities. The company expects an initial internal readout of its 300-patient CLARITY trial at the end of Q3 2026 and plans a public disclosure of early interim results in Q4 2026.

Key facts: cash runway into 2028, ATM terminated in early 2025, ELOC expired December 31, 2025, and 2,882,371 fully diluted shares outstanding. The company emphasizes a cloud-delivered, software-native MedTech model and will pursue an investor-awareness program focused on institutional healthcare investors and physician education.

Aclarion (Nasdaq: ACON) expanded Nociscan availability by establishing an agreement with Source Healthcare in Los Angeles on Feb 3, 2026 to integrate Nociscan into the clinic’s spine and pain pathways.

The partnership will generate real-world evidence comparing Nociscan to anesthetic discography and aims to strengthen clinical validation and payer/provider adoption for the non-invasive MR spectroscopy test.

Aclarion (Nasdaq: ACON, ACONW) closed a $10.4 million common-stock-only financing at $5.18 per share, leaving the company with $21.6 million in cash as of Jan 12, 2026 and a debt-free balance sheet. Management says the transaction materially strengthens the balance sheet, preserves capital-structure integrity and extends the company's operating runway into 2028 under current plans. The company plans to accelerate CLARITY trial enrollment (targeting ~25% of patients by end of Q2 2026), publish multiple investigator-initiated real-world studies, expand MRI manufacturer access (>30% larger available market), launch Nociscan software v2.8 in Q1, and pursue broader US payer engagement.

Aclarion (Nasdaq: ACON / ACONW) provided a 2026 corporate outlook and 2025 operational update centered on its Nociscan platform for chronic low back pain. Key metrics: 2025 annual scan volumes +69% YoY, Q4 2025 volumes +114% YoY. The company reported a debt-free balance sheet with $12.0 million cash as of Dec 31, 2025, following >$22.0 million equity raised in 2025, and expects cash to fund operations into H1 2027. Clinical progress includes the CLARITY trial (7 activated sites) with a goal to enroll ~25% of patients by end of Q2 2026 and an initial internal 3-month readout anticipated in Q3 2026. Additional 2025 milestones: 9 new imaging centers, 22 new physician users, and 4 issued patents.

Aclarion (Nasdaq: ACON) announced first patient enrollments at two additional CLARITY trial sites (Northwestern Medicine and Scripps Health), bringing the number of sites that completed regulatory setup to seven and sites that have enrolled patients to four.

The multi-site pivotal CLARITY trial will randomize up to 300 patients to evaluate Nociscan-guided surgical planning versus blinded care. The company expects an initial interim readout after the first cohort reaches a 3-month follow-up, projected in 3Q 2026, and aims to enroll ~25% of patients by end of Q2 2026. Full enrollment target is mid-2027, with possible early termination if significance is reached earlier.

Aclarion (Nasdaq: ACON) announced publication of a featured Tech Update on its Nociscan solution in the Special Pain Issue of the International Journal of Spine Surgery (IJSS) on Dec 4, 2025. The article highlights a clinical case where a 27-year-old with chronic low back pain had MRI-suspected L4/5 and L5/S1 pathology; a four-level Nociscan exam detected biomarkers at L5/S1 only, guiding the surgeon to perform a single-level artificial disc replacement at L5/S1 that eliminated the patient’s pain and restored activity. The release emphasizes Nociscan as a noninvasive, evidence-supported SaaS platform for distinguishing painful versus nonpainful lumbar discs and notes IJSS’s role in disseminating spine care innovations to an international audience.

Aclarion (NASDAQ: ACON) announced the appointment of Jason Brosniak as Commercial Director, Eastern U.S., effective Dec 2, 2025.

Brosniak brings 20+ years in commercial roles at MedTech firms including Relievant Medsystems, Kyphon, and Intrinsic Therapeutics and will lead adoption and payer engagement for Nociscan across the densely populated Eastern U.S. The hire follows recent UK commercial expansion and coincides with growing demand from real-world evidence trials and the national CLARITY randomized controlled trial.

Nociscan is described as a SaaS platform that noninvasively quantifies chemical biomarkers to help distinguish painful versus nonpainful lumbar discs.